PL3149025T3 - Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania - Google Patents

Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania

Info

Publication number
PL3149025T3
PL3149025T3 PL15796259T PL15796259T PL3149025T3 PL 3149025 T3 PL3149025 T3 PL 3149025T3 PL 15796259 T PL15796259 T PL 15796259T PL 15796259 T PL15796259 T PL 15796259T PL 3149025 T3 PL3149025 T3 PL 3149025T3
Authority
PL
Poland
Prior art keywords
making
methods
cell penetrating
penetrating peptides
peptides
Prior art date
Application number
PL15796259T
Other languages
English (en)
Inventor
Dehua Pei
Ziqing Qian
Original Assignee
Entrada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entrada Therapeutics Inc filed Critical Entrada Therapeutics Inc
Publication of PL3149025T3 publication Critical patent/PL3149025T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL15796259T 2014-05-21 2015-05-21 Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania PL3149025T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462001535P 2014-05-21 2014-05-21
US201562158351P 2015-05-07 2015-05-07
EP15796259.8A EP3149025B1 (en) 2014-05-21 2015-05-21 Cell penetrating peptides and methods of making and using thereof
PCT/US2015/032043 WO2015179691A2 (en) 2014-05-21 2015-05-21 Cell penetrating peptides and methods of making and using thereof

Publications (1)

Publication Number Publication Date
PL3149025T3 true PL3149025T3 (pl) 2019-11-29

Family

ID=54554977

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15796259T PL3149025T3 (pl) 2014-05-21 2015-05-21 Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania

Country Status (17)

Country Link
US (1) US10626147B2 (pl)
EP (2) EP3149025B1 (pl)
JP (2) JP6807831B2 (pl)
CN (2) CN106852146B (pl)
CA (1) CA2949705A1 (pl)
CY (1) CY1121953T1 (pl)
DK (1) DK3149025T3 (pl)
ES (1) ES2739613T3 (pl)
HK (1) HK1232239A1 (pl)
HR (1) HRP20191254T1 (pl)
HU (1) HUE045872T2 (pl)
LT (1) LT3149025T (pl)
PL (1) PL3149025T3 (pl)
PT (1) PT3149025T (pl)
RS (1) RS59119B1 (pl)
SI (1) SI3149025T1 (pl)
WO (1) WO2015179691A2 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10815276B2 (en) * 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
ES2739613T3 (es) 2014-05-21 2020-02-03 Entrada Therapeutics Inc Péptidos que penetran en las células y sus métodos de preparación y su uso
US10456443B2 (en) 2014-08-27 2019-10-29 Ohio State Innovation Foundation Peptidyl calcineurin inhibitors
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3043464A1 (en) * 2016-11-09 2018-05-17 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
US10913773B2 (en) * 2016-11-22 2021-02-09 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
WO2018098282A2 (en) * 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
TW201825510A (zh) * 2016-11-22 2018-07-16 俄亥俄州立創新基金會 細胞穿透肽序列
US11730819B2 (en) * 2016-12-23 2023-08-22 Bicycletx Limited Peptide derivatives having novel linkage structures
KR20230042153A (ko) * 2016-12-23 2023-03-27 바이사이클티엑스 리미티드 Ｍｔ１－ｍｍｐ에 대한 결합용 펩티드 리간드
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
CN108070025B (zh) * 2017-10-24 2019-11-19 中山大学附属口腔医院 一种细胞穿透肽和细胞穿透肽复合物及二者的应用
CA3080617A1 (en) * 2017-10-27 2019-05-02 Ohio State Innovation Foundation Polypeptide conjugates for intracellular delivery of stapled peptides
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CAL-PDZ BINDING DOMAIN CYCLIC PEPTIDYL INHIBITORS
EP3755351A4 (en) 2018-02-22 2021-11-24 Entrada Therapeutics, Inc. COMPOSITIONS AND TREATMENT METHODS FOR MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY
EP3790890A4 (en) * 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
GB201810329D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
EP3817776A4 (en) * 2018-07-02 2022-11-30 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR INTRACELLULAR RELEASE OF NUCLEIC ACIDS
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
GB201900530D0 (en) * 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
CA3137095A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TW202118770A (zh) 2019-07-30 2021-05-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
EP4085064A4 (en) * 2019-12-30 2024-05-29 Ohio State Innovation Foundation LOOP PROTEINS INCLUDING CELL-PENETRATING PEPTIDES
CN113105554B (zh) * 2020-01-13 2022-07-26 广东泰禾医药科技有限公司 一种抗肿瘤融合蛋白及其制法和应用
BR112023012422A2 (pt) 2021-01-24 2023-12-12 Michael David Forrest Inibidores da atp sintase - usos cosmético e terapêutico
WO2022213118A1 (en) * 2021-03-31 2022-10-06 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
EP4337264A1 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions and methods for modulating tissue distribution of intracellular therapeutics
WO2022240758A1 (en) * 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2022240757A1 (en) * 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs
IL311139A (en) * 2021-09-01 2024-04-01 Entrada Therapeutics Inc Compounds and methods for skipping exon 44 in Duchenne muscular dystrophy
AU2022337260A1 (en) * 2021-09-01 2024-04-04 Entrada Therapeutics, Inc. Compositions and methods for skipping exon 45 in duchenne muscular dystrophy
WO2023081893A1 (en) * 2021-11-08 2023-05-11 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides
WO2023178327A1 (en) * 2022-03-17 2023-09-21 Ohio State Innovation Foundation Membrane translocation domains and uses thereof
WO2023205451A1 (en) * 2022-04-22 2023-10-26 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965536A (en) 1993-12-15 1999-10-12 Board Of Regents, The University Of Texas System Methods of inhibiting CXC intercrine molecules
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US6110889A (en) 1996-06-14 2000-08-29 Board Of Regents, The University Of Texas System Peptide tumor cell growth inhibitors
JP3791981B2 (ja) 1996-10-15 2006-06-28 森永乳業株式会社 ペプチド誘導体及び抗真菌剤
WO1998041223A1 (en) 1997-03-20 1998-09-24 The Regents Of The University Of California N-methyl-d-aspartate receptor channel blockers and method for identifying such
CA2224066A1 (en) 1997-10-24 1999-04-24 Universite D'ottawa/ University Of Ottawa Peptides as analgesics
US6388054B1 (en) 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
WO2000032235A1 (de) 1998-11-26 2000-06-08 Pentapharm Ag Transportsystemkonjugate
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
EP1574507A3 (en) 1999-04-30 2005-10-26 SLIL Biomedical Corporation Furo- and pyrano-naphthoquinones and their use in the treatment of cancer
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
BR0010702A (pt) 1999-04-30 2002-02-13 Slil Biomedical Corp Novas quinonas como terapias de doenças
NZ515140A (en) 1999-04-30 2003-07-25 Slil Biomedical Corp Conformationally restricted polyamine analogs as disease therapies for cancer, epilepsy, alzheimers, infections, grafts and others
CA2368801A1 (en) 1999-04-30 2000-11-09 Slil Biomedical Corporation Conjugates as therapies for cancer and prostate diseases
IL141250A0 (en) 1999-06-05 2002-03-10 Univ Leland Stanford Junior Method and composition for inhibiting cardiovascular cell proliferation
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
WO2002010142A1 (en) 2000-08-02 2002-02-07 Slil Biomedical Corporation Cyclic polyamine compounds for cancer therapy
US20030072715A1 (en) 2000-08-02 2003-04-17 Benjamin Frydman Cyclic polyamine compounds for cancer therapy
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
JP4387669B2 (ja) 2000-10-13 2009-12-16 ザイジェン エス．アー． 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達
WO2002057313A2 (en) 2000-10-27 2002-07-25 Consensus Pharmaceuticals, Inc. Receptor-binding compounds and methods for identifying them
US20030167129A1 (en) 2000-10-27 2003-09-04 Nestor John J. Binding compounds and methods for identifying binding compounds
WO2002091989A2 (en) 2000-11-08 2002-11-21 Slil Biomedical Corporation Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
DE60233137D1 (de) 2001-02-16 2009-09-10 Univ R Transporter mit beabstandeten arginin-teilchen
WO2002090503A2 (en) 2001-05-04 2002-11-14 The Scripps Research Institute Anti-microbial peptides and compositions
JP2004537596A (ja) 2001-08-03 2004-12-16 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ オリゴグアニジン輸送因子の二方向合成
CA2463771A1 (en) 2001-10-16 2003-04-24 Slil Biomedical Corporation Oligoamine compounds and derivatives thereof for cancer therapy
AU2002346498A1 (en) 2001-11-30 2003-06-17 Applera Corporation Thermus brockianus nucleic acid polymerases
AU2002364539A1 (en) 2001-12-07 2003-06-23 Cellgate, Inc. Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
EP1461084A2 (en) 2001-12-11 2004-09-29 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
CA2471192C (en) * 2002-01-17 2014-05-20 Canbas Co., Ltd. Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
FR2836474B1 (fr) 2002-02-22 2004-12-24 Synt Em Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique
AU2003241384A1 (en) 2002-05-06 2003-11-17 The Scripps Research Institute Cyclic peptide anti-viral agents and methods
AU2003232077A1 (en) 2002-05-06 2003-11-17 The Scripps Research Institute Cyclic peptide anti-cancer agents and methods
JP2005533820A (ja) 2002-06-26 2005-11-10 セルゲイト， インコーポレイテッド 癌治療のためのポルフィリン−ポリアミン結合体
US20040192665A1 (en) 2002-08-02 2004-09-30 Slil Biomedical Corporation Conjugates of porphyrin compounds with chemotherapeutic agents
US20060128614A1 (en) 2002-09-20 2006-06-15 Jya-Wei Cheng Antimicrobial peptides with reduced hemolysis and methods of their use
AU2003297657A1 (en) 2002-11-29 2004-06-23 Adaptive Therapeutics, Inc. Antifungal therapeutic agents
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
CA2557814A1 (en) 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
WO2006041805A1 (en) 2004-10-04 2006-04-20 Cellgate, Inc. Polyamine analogs as therapeutic agents for ocular diseases
WO2006086773A2 (en) 2005-02-11 2006-08-17 Cellgate, Inc. Polyamine analogs as modulators of cell migration and cell motility
WO2007040535A1 (en) 2005-10-03 2007-04-12 Cellgate, Inc. Use of polyamine analogs for treatment and prevention of intestinal polyps
WO2007055578A1 (en) 2005-11-11 2007-05-18 Leids Universitair Medisch Centrum Cyclic antimicrobial peptides derived from lactoferrin
WO2007070372A2 (en) 2005-12-09 2007-06-21 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
CA2655448C (en) 2005-12-22 2016-09-06 Novabiotics Limited Cyclic antimicrobial peptides
US9181303B2 (en) 2005-12-22 2015-11-10 Novabiotics Limited Treatment of bacterial infections with cyclic antimicrobial peptides
US20100168034A1 (en) * 2006-02-20 2010-07-01 Ewha University-Industry Collaboration Foundation Peptide having cell membrane penetrating activity
EP1991562A2 (en) 2006-02-27 2008-11-19 Technische Universität München Cancer imaging and treatment
WO2007106554A2 (en) 2006-03-14 2007-09-20 Progen Pharmaceuticals, Inc. Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
US20100279918A1 (en) * 2006-03-20 2010-11-04 Burnham Institute For Medical Research Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents
WO2007111993A2 (en) 2006-03-22 2007-10-04 Cellgate, Inc. Polyamine analogs as therapeutic agents for skin diseases
WO2008077194A1 (en) 2006-12-22 2008-07-03 Xenome Ltd Receptor agonists
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
CA2749108C (en) 2008-01-18 2017-06-27 Visen Medical, Inc. Intramolecularly-quenched fluorescent imaging agents
WO2010107832A1 (en) 2009-03-17 2010-09-23 Bracco Imaging Spa Lhrh-ii peptide analogs
WO2011095218A1 (en) 2010-02-05 2011-08-11 Polyphor Ag Template-fixed pep tidomime tics with cxcr7 modulating activity
AU2010344997B2 (en) 2010-02-05 2015-09-10 Polyphor Ag Template - fixed peptidomimetics with CXCR7 modulating activity
WO2011126010A1 (ja) * 2010-04-06 2011-10-13 三菱化学株式会社 癌細胞選択的膜透過性ペプチドおよびその利用
JP2012131743A (ja) * 2010-12-22 2012-07-12 Kyoto Univ 腫瘍集積型抗癌剤
US9744191B2 (en) 2012-03-19 2017-08-29 Yale University Antimicrobial compositions and methods
WO2014053882A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US20150038671A1 (en) 2013-05-30 2015-02-05 Keykavous Parang Efficient Synthesis of CN2097 and RC7 and Their Analogs
WO2015179438A1 (en) 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
ES2739613T3 (es) * 2014-05-21 2020-02-03 Entrada Therapeutics Inc Péptidos que penetran en las células y sus métodos de preparación y su uso
EP3166959A4 (en) 2014-07-11 2017-12-13 C3 Jian, Inc. Targeting peptides that bind s. mutans, constructs comprising such peptides and uses thereof
US10456443B2 (en) 2014-08-27 2019-10-29 Ohio State Innovation Foundation Peptidyl calcineurin inhibitors
WO2016044683A1 (en) 2014-09-19 2016-03-24 Tensive Controls, Inc. Anti-microbial peptides
JP2016065018A (ja) 2014-09-25 2016-04-28 国立大学法人京都大学 Ｃｘｃｒ７結合剤およびｃｘｃｒ７結合剤を含有する医薬組成物
CN105440105B (zh) 2015-12-17 2018-11-27 倪京满 一种具有高稳定性及抗耐药活性的组合抗菌肽的制备和应用

Also Published As

Publication number Publication date
EP3613426A1 (en) 2020-02-26
CN113861268A (zh) 2021-12-31
PT3149025T (pt) 2019-08-01
WO2015179691A3 (en) 2016-02-25
JP2017519041A (ja) 2017-07-13
CA2949705A1 (en) 2015-11-26
EP3149025B1 (en) 2019-06-26
US20170190743A1 (en) 2017-07-06
WO2015179691A9 (en) 2016-03-31
HUE045872T2 (hu) 2020-01-28
HK1232239A1 (zh) 2018-01-05
EP3149025A2 (en) 2017-04-05
HRP20191254T1 (hr) 2019-10-18
SI3149025T1 (sl) 2019-09-30
JP6807831B2 (ja) 2021-01-06
CN106852146A (zh) 2017-06-13
LT3149025T (lt) 2019-09-25
RS59119B1 (sr) 2019-09-30
DK3149025T3 (da) 2019-07-22
EP3613426A9 (en) 2023-05-24
EP3149025A4 (en) 2018-02-21
ES2739613T3 (es) 2020-02-03
CY1121953T1 (el) 2020-10-14
US10626147B2 (en) 2020-04-21
WO2015179691A2 (en) 2015-11-26
JP2020169170A (ja) 2020-10-15
CN106852146B (zh) 2021-08-13

Similar Documents

Publication Publication Date Title
HK1232239A1 (zh) 細胞穿透肽及其製造和使用方法
HK1250481A1 (zh) 經過修飾的t細胞及其製備和使用方法
HK1243102A1 (zh) 抗cd79b抗體和使用方法
HRP20181359T1 (hr) Anti-jagged1 protutijela i postupci uporabe
IL251868B (en) Anti-tim3 antibodies and methods of use
IL250415B (en) Antibodies against pd-l and methods of using them
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use
GB201419472D0 (en) Method of using and electrochemical device
IL247448A0 (en) Peptides and methods of use
GB201403107D0 (en) Permeability and transformation of cells
AU2014901577A0 (en) Thermo-Electrochemical Cell and Method of Use